Tetrahydrobiopterin /kg

Phase 1Small molecule

Tetrahydrobiopterin /kg is one of 3 small molecule programs targeting Intermittent Claudication. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intermittent ClaudicationRecruiting

Intermittent ClaudicationPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Intermittent Claudication

#DrugCompanyPhaseTrials

Metformin ER

Teva

Phase 3

1 2

L-Arginine

Mario Negri Institute for Pharmacological Research

Phase 1

1 3

Tetrahydrobiopterin /kg

LLouis Messina

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Intermittent Claudication

NCT04800692

Clinical

Trials by Indication[1]

Intermittent Claudication1 trial

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

Recruiting·LLouis Messina·Phase 1·NCT04800692·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tetrahydrobiopterin /kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tetrahydrobiopterin /kg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tetrahydrobiopterin /kg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Louis Messina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LLouis Messina

Tetrahydrobiopterin /kg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Intermittent Claudication1 trial

References

Drug Info

Quick Facts

Related News